Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | IM |
subcu administration instead of IM/ Incorrect Route of Administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On 15-SEP-2025, the patient received the 1st dose of Priorix (intramuscular). On 15-SEP-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: subcu administration instead of IM/ Incorrect Route of Administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-SEP-2025 The pharmacist enquired if the intramuscular administration of the medication, instead of the subcutaneous route, constituted a contraindication. He queried if this had any implications for the patient and whether any further actions were required after the situation. HCP confirmed that the patient was administered the Priorix shot intramuscularly.